Breast Cancer Metastatic Clinical Trials

132 clinical trials for Breast Cancer Metastatic across international registries, including 51 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer — RECRUITING · PHASE2
• The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer — RECRUITING · PHASE2
• Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy — RECRUITING · PHASE2
• Decision Support Tool for Patients With Advanced Breast Cancer — RECRUITING · NA
• Screening For BCRL In Targeted Therapy For Breast Cancer — RECRUITING
• Trial of Trastuzumab Deruxtecan in Previously Treated HER2 — RECRUITING · PHASE2
• A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer — RECRUITING · PHASE1
• HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity — RECRUITING
• Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device — RECRUITING · NA
• A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer. — RECRUITING · PHASE1
• Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. — RECRUITING · PHASE3
• Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer — RECRUITING · PHASE1
• HER2-PET Imaging in HER2-low Breast Cancers — RECRUITING · PHASE1
• PIK3CA Mutational Status Assessment — RECRUITING
• Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer (mBC) Patients, — RECRUITING
• Nutrition Awareness Among Women With Non-Metastatic Breast Cancer — RECRUITING · NA
• SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells — RECRUITING · PHASE1
• Target-specific immunoPET Imaging of Breast Cancer — RECRUITING · PHASE1
• Sapu003 in Advanced mTOR-sensitive Solid Tumors — RECRUITING · PHASE1
• A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1 — RECRUITING · PHASE1
• To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China. — RECRUITING
• Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy — RECRUITING · PHASE1
• Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Cancer — RECRUITING
• Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer — RECRUITING · PHASE2
• Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment — RECRUITING
• HERTHENA-BREAST-01: A PHASE 1B/2, MULTICENTER, OPEN-LABEL, DOSE FINDING STUDY TO EVALUATE THE SAFETY AND ANTITUMOR ACTIVITY OF PATRITUMAB DERUXTECAN IN PARTICIPANTS WITH HER2 POSITIVE UNRESECTABLE LOCALLY ADVANCED BREAST CANCER OR METASTATIC BREAST CANCER — RECRUITING · PHASE1
• RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study — RECRUITING
• Immun Checkpoint Washout in Patients With Invasive Ductal Breast Cancer — RECRUITING · NA
• A Real World Study of Sacituzumab Govitecan — RECRUITING
• Integrin αvβ6-targeted PET in Malignant Tumors — RECRUITING
• 21-gene in Elder Breast Cancer Patients With Lymph Node Metastasis — RECRUITING
• Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer — RECRUITING · PHASE3
• Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis — RECRUITING · PHASE1
• Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study — RECRUITING
• Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers — RECRUITING
• A RANDOMIZED, OPEN-LABEL STUDY COMPARING THE BRIA-IMT REGIMEN IN COMBINATION WITH CHECK POINT INHIBITOR VS PHYSICIAN'S CHOICE IN METASTATIC BREAST CANCER — RECRUITING
• Drug Sensitivity of Hydrothorax and Ascite Organoids from Breast Cancer — RECRUITING
• TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer — RECRUITING · PHASE1
• Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd — RECRUITING · PHASE1
• Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer — RECRUITING · PHASE2
• PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer — RECRUITING · PHASE2
• A PHASE 3, RANDOMIZED, MULTI-CENTER, OPEN-LABEL STUDY OF DB-1303 VERSUS INVESTIGATOR¿S CHOICE CHEMOTHERAPY IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-LOW, HORMONE RECEPTOR POSITIVE (HR+) METASTATIC BREAST CANCER PATIENTS WHOSE DISEASE HAS PROGRESSED ON ENDOCRINE THERAPY (ET) (DYNASTY-BREAST02) — RECRUITING · PHASE3
• TUCATINIB, TRASTUZUMAB AND CAPECITABINE WITH BRAIN AND/OR SPINAL RADIOTHERAPY (XRT) IN PATIENTS WITH HER2+, HER2 MUTATED AND/OR HER2- AMPLIFIED METASTATIC BREAST CANCER AND LEPTOMENINGEAL DISEASE: A MULTI-CENTRE PHASE II, SINGLE ARM FEASIBILITY STUDY. — RECRUITING · PHASE2
• A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SACITUZUMAB GOVITECAN VERSUS TREATMENT OF PHYSICIAN¿S CHOICE IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+)/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HER2-) (HER2 IHC0 OR HER2-LOW [IHC 1+, IHC 2+/ISH-]) INOPERABLE, LOCALLY ADVANCED, OR METASTATIC BREAST CANCER AND HAVE RECEIVED ENDOCRINE THERAPY — RECRUITING · PHASE3
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF PEMBROLIZUMAB PLUS CHEMOTHERAPY VERSUS PLACEBO PLUS CHEMOTHERAPY FOR THE TREATMENT OF CHEMOTHERAPY-CANDIDATE HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) LOCALLY RECURRENT INOPERABLE OR METASTATIC BREAST CANCER (KEYNOTE-B49) — RECRUITING · PHASE3
• AN OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY EVALUATING THE ACTIVITY OF LASOFOXIFENE RELATIVE TO FULVESTRANT FOR THE TREATMENT OF PRE- AND POSTMENOPAUSAL WOMEN WITH LOCALLY ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER WITH AN ESR1 MUTATION — RECRUITING
• MONARCHER: A PHASE 2, RANDOMIZED, MULTICENTER, 3-ARM, OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS TRASTUZUMAB WITH OR WITHOUT FULVESTRANT TO STANDARD-OF-CARE CHEMOTHERAPY OF PHYSICIAN'S CHOICE PLUS TRASTUZUMAB IN WOMEN WITH HR+, HER2+ LOCALLY ADVANCED OR METASTATIC BREAST CANCER. — RECRUITING · PHASE2
• RANDOMIZED PHASE II STUDY COMPARING TWO DIFFERENT SCHEDULES OF PALBOCICLIB PLUS SECOND LINE ENDOCRINE THERAPY IN WOMEN WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE ADVANCED/METASTATIC BREAST CANCER. — RECRUITING · PHASE2
• A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY OF MM-302 PLUS TRASTUZUMAB VS. CHEMOTHERAPY OF PHYSICIAN'S CHOICE PLUS TRASTUZUMAB IN ANTHRACYCLINE NAIVE PATIENTS WITH LOCALLY ADVANCED/METASTATIC HER2-POSITIVE BREAST CANCER — RECRUITING
• A RANDOMIZED DOUBLE-BLIND, PLACEBO CONTROLLED, PHASE II/III STUDY OF BKM120 PLUS PACLITAXEL IN PATIENTS WITH HER2 NEGATIVE INOPERABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER, WITH OR WITHOUT PI3K PATHWAY ACTIVATION — RECRUITING · PHASE2

Refine this search